Inflammation Shows Up Before CKM Looks Sick

By the time cardiovascular-kidney-metabolic syndrome has a name, many people will hear it as a warning about diseases they do not yet have: heart disease, kidney disease, diabetes. The unsettling part of a new analysis is that the body may already be sending a quieter signal earlier than that.

Researchers using U.S. National Health and Nutrition Examination Survey data from 2015 to 2018 found that high-sensitivity C-reactive protein, or hs-CRP, increased across the stages of CKM syndrome, with the largest jump occurring between stage 0 and stage 1. The study included 4,315 adults, with an average age of 48, and half were women. It was published in the European Journal of Preventive Cardiology and presented at the European Society of Cardiology Congress 2026.

CKM syndrome, a framework introduced by the American Heart Association in 2023, groups together linked risks involving obesity, type 2 diabetes, kidney disease and cardiovascular disease. Stage 1 refers to excess or unhealthy body fat, before diagnoses such as diabetes, kidney disease or established heart disease appear.

In this analysis, average hs-CRP nearly doubled from stage 0 to stage 1 and moved past 2 mg/L, a level commonly used to indicate higher cardiovascular risk. After that, levels remained above that threshold, rising more modestly at stage 2 and then flattening.

That does not prove inflammation is causing the syndrome to progress. This was a cross-sectional study — a look at one point in time, not a follow-up of the same people over years — so it can show association, not sequence or cause. hs-CRP is also a broad marker of inflammation, not a diagnosis and not, on its own, a treatment plan.

Still, the pattern matters because stage 1 is the part of the pathway most likely to be dismissed as pre-illness, the period when someone may be told they are “at risk” but not yet sick enough to command urgency. The study suggests that, biologically, the body may already be under strain by then.

The authors argue that hs-CRP could be useful as an inexpensive warning marker while longer studies test whether earlier prevention changes outcomes. That is a narrower claim than saying an inflammation blood test should now direct care. But it is also a harder one to ignore: the first measurable trouble may begin before the first diagnosis does.